News for Maravai LifeSciences Holdings, Inc. (MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) is one of the 10 best healthcare penny stocks to buy according to analysts. On June 26, William Blair reaffirmed its “Market Perform” rating for Maravai stock. The key factor influencing this move is the leadership changes at Maravai. Maravai has undergone a complete leadership overhaul since December last year. […]

There's a growing belief that agentic AI could fundamentally transform workforce productivity.

Maravai LifeSciences, with the ticker MRVI, has appointed Bernd Brust as its new CEO and as a member of its Board of Directors, effective immediately. He replac

Bernd Brust appointed as new CEO of Maravai LifeSciences (MRVI), effective immediately. Focus on accelerating innovation and improving financial perform

**media[649451]**

TriLink BioTechnologies has entered a non-exclusive License and Supply Agreement with Quantoom Biosciences. This collaboration grants Quantoom access to TriLink

**media[633505]**

**media[633491]**

In recent developments, the financial services firm Craig-Hallum has updated its price target for Maravai LifeSciences (MRVI). The adjustment sees the price tar

Maravai LifeSciences Holdings, Inc. MRVI reported mixed results for the first quarter on Monday. The company posted quarterly losses of 8 cents per share which...

Revenue: $47 million for Q1 2025.Nucleic Acid Production (NAP) Revenue: $29 million in Q1 2025.Biologic Safety Testing (BST) Revenue: $18 million in Q1 2025.GA

May 12, 2025 / 09:00PM GMTOperator Please stand by. We're about to begin. Good afternoon, everyone, and welcome to the Maravai LifeSciences Q1 2025 results earn

The following slide deck was published by Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ETCompany ParticipantsDebra Hart - Head, IRKevin...

SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) ( MRVI), a global provider of life science reagents and serv

Maravai LifeSciences (MRVI) reported first-quarter revenue of $46.9 million, surpassing the analysts' estimate of $44.01 million. The company attributed this pe

Quarterly Revenue: $46.9 million, surpassing the estimated $44.01 million.Net Loss: $(52.9) million, including a goodwill impairment of $12.4 million.Earnings

LOS ANGELES, May 05, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of share

\nMRVI Investors with Losses Encouraged to Contact the Firm Before May 5th Deadline\n\nSAN FRANCISCO, May 03, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdi